Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.
Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group.
复制标题
DOI：
10.1056/nejm199807303390503
复制
发表时间：
1998-07-30
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
背景技术背景：抗病毒药物的长期治疗已被证明可以防止生殖器和orofacial单纯疱疹病毒（HSV）疾病复发，但它是不确定的预防性治疗是否可以防止复发的眼部HSV diseases.METHODS：我们随机分配703免疫功能正常的患者谁有眼部HSV疾病在前一年内接受400毫克的阿昔洛韦或安慰剂口服每日两次。研究结果是在12个月的治疗期和6个月的观察期内眼部或非眼部HSV疾病的发生率。结果：在12个月的治疗期内，任何类型的眼部HSV疾病复发的累积概率在阿昔洛韦组为19%，在安慰剂组为32%（P
BACKGROUND: Long-term treatment with antiviral agents has been shown to prevent recurrences of genital and orofacial herpes simplex virus (HSV) disease, but it is uncertain whether prophylactic treatment can prevent recurrences of ocular HSV disease.METHODS: We randomly assigned 703 immunocompetent patients who had had ocular HSV disease within the preceding year to receive 400 mg of acyclovir or placebo orally twice daily. The study outcomes were the rates of development of ocular or nonocular HSV disease during a 12-month treatment period and a 6-month observation period.RESULTS: The cumulative probability of a recurrence of any type of ocular HSV disease during the 12-month treatment period was 19 percent in the acyclovir group and 32 percent in the placebo group (P